TMCnet News
Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
[December 28, 2020]
Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
â Company plans to complete rolling submission in the first half of 2021 â
â The pivotal Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression or death by 67%, extending PFS of
non-pancreatic NET patients with an acceptable risk/benefit ratio â
â The pivotal Phase III SANET-p trial demonstrated surufatinib reduced risk of progression or death by 51%, extending PFS of
pancreatic NET patients with an acceptable risk/benefit ratio â
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of .
Hutchison China MediTech LimitedDecember 28, 2020 GMT
– Company plans to complete rolling submission in the first half of 2021 –
– The pivotal Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression or death by 67%, extending PFS of non-pancreatic NET patients with an acceptable risk/benefit ratio –
– The pivotal Phase III SANET-p trial demonstrated surufatinib reduced risk of progression or death by 51%, extending PFS of pancreatic NET patients with an acceptable risk/benefit ratio –
Share:
Relief or the
Company ), a biopharmaceutical company with its lead compound RLF-100
TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today announced the appointment of Christiaan ( Chris ) L.J.J. Stijnen as Chief Commercial Officer (CCO) effective December 21, 2020. Mr. Stijnen will strengthen the management team in all activities pertaining to the commercialization of RLF-100(TM) and other future assets.
Mr. Stijnen is a highly experienced pharmaceutical executive with a successful track record in marketing, general management, access strategy and product development across a variety of indications. Prior to joining Relief, he had an impressive career with Bristol-Myers Squibb, where he was responsible for the marketing and commercialization of the company s portfolio in various international subsidiaries between 2005 and March 2020. Most recently he was VP Product & Portfolio Strategy and Interim Head Commercial Strategy and Capabilit
EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Personnel
Relief Appoints Chris L.J.J. Stijnen as Chief Commercial Officer
21.12.2020 / 07:00
Relief or the
Company ), a biopharmaceutical company with its lead compound RLF-100
TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today announced the appointment of Christiaan ( Chris ) L.J.J. Stijnen as Chief Commercial Officer (CCO) effective December 21, 2020. Mr. Stijnen will strengthen the management team in all activities pertaining to the commercialization of RLF-100(TM) and other future assets.
Mr. Stijnen is a highly experienced pharmaceutical executive with a successful track record in marketing, general management, access strategy and product development across a variety of indications. Prior to joining Relief, he had an impressive career with Bristol-Myers Squibb, where he was responsible for the marketing and commercialization of the company s portfolio in various i
GENEVA, SWITZERLAND / ACCESSWIRE / December 21, 2020 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) (
Relief or the
Company ), a biopharmaceutical company with its lead compound RLF-100
TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today announced the appointment of Christiaan ( Chris ) L.J.J. Stijnen as Chief Commercial Officer (CCO) effective December 21, 2020. Mr. Stijnen will strengthen the management team in all activities pertaining to the commercialization of RLF-100(TM) and other future assets.
Mr. Stijnen is a highly experienced pharmaceutical executive with a successful track record in marketing, general management, access strategy and product development across a variety of indications. Prior to joining Relief, he had an impressive career with Bristol-Myers Squibb, where he was responsible for the marketing and commercialization of the company s portfolio in various international subsidiaries between 2005 and March 2020